share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K：重大事件
美股SEC公告 ·  08/17 05:08

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc. has received two deficiency letters from The Nasdaq Stock Market. The first, received on August 13, 2024, notified the company of its failure to meet the Minimum Bid Price Requirement, as its common stock did not maintain the required $1.00 per share minimum closing bid price for 30 consecutive business days. The second letter, received on August 15, 2024, indicated a deficiency in meeting the Stockholders' Equity Requirement, with reported equity of $1,322,274, below the required $2,500,000. TransCode Therapeutics plans to request a hearing before the Nasdaq Hearings Panel to address these deficiencies and has reported pro forma stockholders' equity of approximately $3.7 million, considering net proceeds from a July 2024 equity offering. The company's securities are at risk of suspension or delisting, and there is no assurance that the Panel will grant an extension or that the company will regain compliance with Nasdaq's continued listing requirements.
TransCode Therapeutics, Inc. has received two deficiency letters from The Nasdaq Stock Market. The first, received on August 13, 2024, notified the company of its failure to meet the Minimum Bid Price Requirement, as its common stock did not maintain the required $1.00 per share minimum closing bid price for 30 consecutive business days. The second letter, received on August 15, 2024, indicated a deficiency in meeting the Stockholders' Equity Requirement, with reported equity of $1,322,274, below the required $2,500,000. TransCode Therapeutics plans to request a hearing before the Nasdaq Hearings Panel to address these deficiencies and has reported pro forma stockholders' equity of approximately $3.7 million, considering net proceeds from a July 2024 equity offering. The company's securities are at risk of suspension or delisting, and there is no assurance that the Panel will grant an extension or that the company will regain compliance with Nasdaq's continued listing requirements.
TransCode Therapeutics，Inc.已經收到納斯達克股票市場發出的兩封違規通知函。第一封信於2024年8月13日收到，通知公司未達到最低買盤價要求，因爲其普通股連續30個營業日未能維持每股1.00美元的最低買盤價。第二封信於2024年8月15日收到，表明未達到股東權益要求，報告的股東權益爲1,322,274美元，低於要求的2,500,000美元。TransCode Therapeutics計劃在納斯達克聽證會之前提出聽證申請，以解決這些缺陷，並報告約370萬美元的股東權益，考慮到2024年7月的股權發行淨收益。公司證券面臨被暫停交易或除牌的風險，並不能保證聽證會將予以延期或公司將符合納斯達克的繼續上市要求。
TransCode Therapeutics，Inc.已經收到納斯達克股票市場發出的兩封違規通知函。第一封信於2024年8月13日收到，通知公司未達到最低買盤價要求，因爲其普通股連續30個營業日未能維持每股1.00美元的最低買盤價。第二封信於2024年8月15日收到，表明未達到股東權益要求，報告的股東權益爲1,322,274美元，低於要求的2,500,000美元。TransCode Therapeutics計劃在納斯達克聽證會之前提出聽證申請，以解決這些缺陷，並報告約370萬美元的股東權益，考慮到2024年7月的股權發行淨收益。公司證券面臨被暫停交易或除牌的風險，並不能保證聽證會將予以延期或公司將符合納斯達克的繼續上市要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間